利培酮
药代动力学
药理学
医学
药品
药效学
抗精神病药
食品药品监督管理局
奥氮平
氟哌啶醇
口服
加药
硫利达嗪
非定型抗精神病薬
分配量
麻醉
生物利用度
氯氮平
精神科
精神分裂症(面向对象编程)
作者
Larry Ereshefsky,Cynthia A. Mascareñas
摘要
Clinicians face a dilemma when choosing between short-acting atypical antipsychotics and long-acting conventional antipsychotics. Atypical antipsychotics offer better safety and efficacy, while depot formulations of conventional antipsychotics provide more reliable drug delivery, reduced differences in peak and trough plasma levels of drug, and greater dosing precision. Risperidone was recently approved by the U.S. Food and Drug Administration as the first atypical long-acting antipsychotic medication, given as biweekly gluteal injections. This long-acting formulation is synthesized using a microsphere encapsulation process, and gradual hydrolysis of the copolymer encapsulating the drug provides a steady release of medication. Consistent with other long-acting medications, plasma drug level fluctuation is reduced more with long-acting than with oral risperidone. Analyses are currently underway to further examine safety outcomes with long-acting risperidone.
科研通智能强力驱动
Strongly Powered by AbleSci AI